Recursion Pharmaceuticals, Inc. announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of the company, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. Dr. Hershberg has served as a member of it?s Board since May 2020. He is the Chief Executive Officer, President, and Chair of the Board of HilleVax, Inc. Since 2020, he has also been a Venture Partner at Frazier Healthcare Partners.

Dr. Hershberg formerly served as the executive vice president and head of business development and global alliances at Celgene (acquired by Bristol-Myers Squibb in 2019). He joined Celgene in 2014 and was employed in positions of ascending responsibility, including his role as Chief Scientific Officer from January 2016 to March 2020. Before Celgene, he served several roles at VentiRx Pharmaceuticals, which he co-founded in 2006 and was Chief Executive Officer from September 2012 until the company?s acquisition by Celgene in February 2017.

Dr Hershberg is a member of the board of directors of Adaptive Biotechnologies, Scientific Advisory Board of Danaher Corporation, Dragonfly Therapeutics, Skyhawk Therapeutics, and the Institute for Protein Design at the University of Washington. Rob holds a Ph.D. in biology from the University of California, San Diego?s Affiliated Ph.D. program with the Salk Institute and an M.D. and a B.A. from the University of California, Los Angeles.